The company provides integrated, end-to-end new drug development and production services for the global biomedical industry. The company's main business can be divided into five major segments: chemical business (wuxiTesting), biology business (wuxiBiology), cell and gene therapy CTDMO business (wuxiTU), and domestic new drug development service department (wuxiDSU). The scope of services covers the entire process from concept generation to commercial production, and the service area includes China, the United States, Europe and other regions. Company honors include Baihua Association's “Enterprise of the Year Award”, Sina Pharmaceuticals's “Most Influential Enterprise in China's Pharmaceutical Industry”, and “China's 100 Model Employers” for four consecutive years.